Quelle chimiothérapie périopératoire pour les tumeurs de vessie infiltrant le muscle ?

Abstract

The current standard of care for patients with muscle invasive bladder cancer is cisplatin-based neoadjuvant chemotherapy followed by pelvic lymph node dissection during radical cystectomy. There are no data for the administration of non-cisplatin-based neoadjuvant chemotherapy such as carboplatin combinations. For the majority of nonurothelial bladder cancers and for patients who cannot receive cisplatin, direct surgical resection is indicated. Data for adjuvant cisplatin-based chemotherapy remains weak. Muscle invasive bladder cancers are heterogeneous and have widely variable clinical outcomes and responses to conventional chemotherapy. Therefore, there is an urgent need to develop and evaluate predictive factors using biologybased approach to the classification of bladder cancer to inform clinical management.